ImmunityBio's total assets for Q1 2026 were $646.64M, an increase of 28.84% from the previous quarter. IBRX total liabilities were $1.52B for the fiscal quarter, a 51.35% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.